SL Science
Develops licensed immune-cell therapies alongside Taiwan exosome and hair-care products.
Something off on this page? Send us feedback.
Profile
Sells exosome-based cosmetics and hair-care products in Taiwan while developing preclinical CD-19 Armed-T and donor-derived gamma delta T-cell therapies through licensed technology and external collaborators; commercial revenue still comes from the legacy portfolio.
Operates Exosome Products in Taiwan, including bovine-milk-derived exosome concentrate, skin-care products, and tangerine-extract hair and scalp-care products. CD-19 Armed-T Products target blood cancers, while GDT cell therapy Products use donor-derived gamma delta T cells for pancreatic cancer and glioblastoma; both programs remain preclinical.
Develops the therapeutic programs through licensed technology, external manufacturing, and academic and clinical collaborations rather than a fully integrated model. Commercial revenue comes from the legacy cosmetic and plant-extract portfolio, which management intends to phase out as cell therapies advance. Therapeutic development depends on licensed rights, clinical-grade material and IND-enabling toxicology; no candidate has an IND, human-trial record, or FDA approval.
Company facts
Key statistics
Year to date −65.4% · Average volume (30d) 70.7K
Analysts
No analyst consensus on record.
Earnings
Not reported.
Financial highlights
Not reported.
Dividends
No dividends on record.
Ownership
Shares outstanding 560.76M · Float 226.91M · 40.5% free float
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Gilead Sciences
Approved CD19 CAR-T option for B-cell blood cancers.
- Novartis (ADR)
Approved CD19 CAR-T franchise in B-cell leukemia and lymphoma.
- Bristol-Myers Squibb
Personalized CD19 CAR-T for a broad range of B-cell cancers.
- IN8bio
Gamma-delta programs include a clinical glioblastoma candidate.
- Adicet Bio
Allogeneic gamma-delta CAR-T platform for cancer and autoimmunity.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SL Science | $2.70 | 0.00% | $1.51B | — | — | 689.1 | — |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| IN8bio | $1.04 | +0.82% | $9.9M | — | — | — | — |
| Adicet Bio | $9.06 | +0.17% | $84.7M | — | — | — | — |
| Median | 18.9 | 16.0 | 5.3 | +5.7% |